Key Takeaways
- PURE Bioscience reported fiscal first-quarter net product sales of $707,000, up from $555,000 year over year.
- Net loss narrowed to $464,000 for the quarter ended October 31, 2025.
- PURE Control® is now being used on leafy greens destined for commercial sale.
- The company reported continued momentum in produce and transportation markets.
- Management highlighted progress with both direct customers and distribution partners.
PURE Bioscience Reports Fiscal First-Quarter Financial Results
PURE Bioscience, Inc. (OTCQB: PURE), developer of the patented silver dihydrogen citrate (SDC) antimicrobial technology, has reported financial results for its fiscal first quarter ended October 31, 2025.
Net product sales for the quarter reached $707,000, compared to $555,000 in the same period last year. The $152,000 increase was attributed to higher sales across the company’s end-user customer base. The company reported a net loss of $464,000 for the quarter, compared with a net loss of $689,000 a year earlier.
Net loss excluding share-based compensation was $430,000, compared to $632,000 in the prior-year period. Net loss per share was reported at ($0.00) for the quarter, compared to ($0.01) in the fiscal first quarter of 2024.
PURE Control® Gains Traction in Commercial Produce Markets
PURE Bioscience reported continued growth in sales of its seasonal direct food-contact solution, PURE Control®. The company stated that the product is now actively being used to treat leafy greens destined for commercial sale, representing a milestone in market adoption and customer confidence.
According to the company, this progress reflects expanding use of its SDC-based antimicrobial solutions within the produce industry. PURE Bioscience also noted ongoing growth in the transportation sector, where it is supplying SDC-powered sanitation technology and equipment to major trucking fleets through distribution partners.
PURE Bioscience Expands Market Presence Across Multiple Sectors
As part of an update to a prior announcement issued in late October, the company highlighted momentum across several end markets. In addition to produce, PURE Bioscience reported progress in the beverage, dairy, and transportation industries, supported by its distribution network and recent product introductions.
Jeff Kitchell, President of PURE Bioscience, said the year-over-year sales growth reflects improvements in both direct customer engagement and partner-driven distribution.
“Our fiscal first quarter year-over-year sales growth shows the progress we have made with our direct customers and distribution network,” Kitchell said. “We are continuing to grow our core produce business. At the same time, we are working closely with our distribution partners in the beverage and dairy industry to roll out our new membrane treatment solutions.”
